Anti-IL17A, Ixekizumab, for treatment-resistant chronic venous leg ulcers: A phase II randomized, double-blind, placebo-controlled pilot trial.

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

Keyphrases